40+
contributed to its development.
200m
representing the participating patient organizations.
105 533
own it as an aspiration to embed the perspective of patients and caregivers systematically in our decision-making.
We recognize the importance of patients and caregivers understanding what they can expect from Novartis.
Our Commitment – reporting 2022 progress
87%
in general medicines obtained patient insights before first-in-human trials (healthy volunteers).
7 302
94% requests approved for 55 compounds in 80 countries - providing access to locally unlicensed Novartis medicines. At the end of 2022, more than 9 700 patients were receiving treatment through MAPs.
74
comprising 85 clinical trials, had a patient engagement component to obtain the patient perspective on the design and/or conduct of clinical trials.
202
included Patient Reported Outcomes (PRO) conducted in 77 countries.
191
from Phase 1-4 clinical trials sent to investigators to share with 35 500 trial participants and posted on novartis.com/clinicaltrials.
54.2m